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A B S T R A C T
Purpose
The randomized HD2000 trial compared six cycles of ABVD (doxorubicin, bleomycin, vinblastine,
and dacarbazine), four escalated plus two standard cycles of BEACOPP (bleomycin, etoposide,
doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone), and six cycles of COPP-
EBV-CAD (cyclophosphamide, lomustine, vindesine, melphalan, prednisone, epidoxorubicin,
vincristine, procarbazine, vinblastine, and bleomycin; CEC) in patients with advanced-stage
Hodgkin lymphoma. After a median follow-up of 42 months, patients who received BEACOPP were
reported to have experienced better progression-free survival (PFS) but not better overall survival
(OS) results than those receiving ABVD.We here report a post hoc analysis of this trial after amedian
follow-up of 10 years.
Patients and Methods
Three hundred seven patients were enrolled, 295 of whom were evaluable. At the time of our
analysis, the median follow-up for the entire group was 120 months (range, 4 to 169 months).
Results
The 10-year PFS results for the ABVD, BEACOPP, and CEC arms were 69%, 75%, and 76%,
respectively; corresponding OS results were 85%, 84%, and 86%. Overall, 13 secondmalignancies
were reported: one in the ABVD arm and six each in the BEACOPP and CEC arms. The cumulative
risk of developing secondmalignancies at 10 years was 0.9%, 6.6%, and 6%with ABVD, BEACOPP,
and CEC, respectively; the risk with either BEACOPP or CEC was signiﬁcantly higher than that
reported with ABVD (P = .027 and .02, respectively).
Conclusion
With these mature results, we conﬁrm that patients with advanced Hodgkin lymphoma have similar
OS results when treated with ABVD, BEACOPP, or CEC. However, with longer follow-up, we were
not able to conﬁrm the superiority of BEACOPP over ABVD in terms of PFS, mainly because of
higher mortality rates resulting from second malignancies observed after treatment with BEACOPP
and CEC.
J Clin Oncol 34:1175-1181. © 2015 by American Society of Clinical Oncology
INTRODUCTION
Over the last 40 years, major advances have been
achieved in the treatment of patients with
advanced Hodgkin lymphoma (HL).1 Since its
introduction in 1975, the combination of dox-
orubicin, bleomycin, vinblastine, and dacarbazine
(ABVD) has become a standard of care for these
patients.2 After six to eight cycles of this regimen,
approximately 70% of these patients can be cured,
and 50% of those who experience relapse or
progression of disease can be treated with
intensiﬁed salvage therapies, including high-dose
therapy followed by stem-cell rescue (SCT).3
However, in the 1980s, several groups began to
develop novel combinations in an attempt to
improve cure rates for the disease by increasing
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the activity of initial therapy, thereby reducing the need for salvage
treatments. Initially, investigators tested a sequential combination
of ABVD andMOPP (mechlorethamine, vincristine, procarbazine,
and prednisone) or more complex regimens that included several
additional active drugs.4-6 More importantly, investigators of the
German Hodgkin Study Group (GHSG) developed the BEACOPP
regimen, consisting of bleomycin, etoposide, doxorubicin, cyclo-
phosphamide, vincristine, procarbazine, and prednisone, which was
administered at escalated or standard doses.7,8
The BEACOPP regimen, particularly when administered at
escalated doses (e-BEACOPP), was associated with better response
rates and higher efﬁcacy compared with hybrid regimens when
used to treat advanced HL. These results have prompted several
investigators to adopt it as the new standard for advanced HL,
although many physicians have been reluctant to abandon
ABVD, as a result of its high activity, its excellent tolerability,
and the relative absence of major early and late complications of
therapy.
Investigators recently published the results of four random-
ized trials comparing ABVD and BEACOPP, and all demonstrated
similar ﬁndings: comparable survival rates but lower rates of
disease progression after treatment with BEACOPP, particularly for
patients with high-risk disease.9-12 These studies also demonstrated
increased rates of adverse events during and after the administration
of BEACOPP compared with those after ABVD, suggesting the need
for prolonged survival analysis of these trials.
One of these trials, HD2000, aimed to compare ABVD,
BEACOPP, and COPP-EBV-CAD (CEC), the latter of which
consists of cyclophosphamide, lomustine, vindesine, melphalan,
prednisone, epidoxorubicin, vincristine, procarbazine, vinblastine,
and bleomycin (a modiﬁed version of the original hybrid, MOPP-
EBV-CAD5), as initial therapy for advanced HL. We published our
initial results in 2009 after a median follow-up of 42 months.9 In
this report, we describe the post hoc analysis of mature results of
this trial after a median follow-up of 10 years.
PATIENTS AND METHODS
Patients
The HD2000 trial was conducted for previously untreated patients
with biopsy-proven classic HL. Patients in this trial had clinical stage IIB,
III, or IV disease; were older than 16 years of age; and had no cardiac,
pulmonary, hepatic, or renal dysfunctions, unless thought to be directly
related to HL. Pregnant or lactating women and patients with prior
malignancy, HIV positivity, or Eastern Cooperative Oncology Group
(ECOG) performance status greater than 3 were ineligible for the study.
All patients underwent clinical staging according to the Cotswold
modiﬁcations of the Ann Arbor criteria.13 Bulky disease was deﬁned as a
thoracic mass with a diameter$ 6 cm or any extramediastinal mass greater
than 10 cm in diameter on computed tomography.
This study fully complied with all provisions of the Declaration of
Helsinki and was conducted in accordance with Good Clinical Practice
rules. All patients provided written informed consent to participate.
Patients were randomly assigned to receive six cycles of ABVD, four
cycles of e-BEACOPP followed by two cycles of standard-dose BEACOPP
(s-BEACOPP), or six cycles of CEC (Fig 1). Drug doses, time schedules,
and study procedures were provided in our previous report.9
At the end of chemotherapy, radiotherapy (RT) was administered to
sites of previously deﬁned bulky disease or to slowly or partially responding
sites, with recommended doses of 30 to 36 Gy, as deﬁned in the original
report.9 Although some underwent positron emission tomography (PET)
imaging, response in this trial was assessed by computed tomography alone.
Statistical Methods
The primary end points of this long-term study were progression-free
survival (PFS), cumulative incidence of secondary malignancies (con-
sidering death as a competing risk), and frequency of late adverse events.
Secondary end points were overall survival (OS) and failure-free survival
(FFS), to allow comparison with our previously reported results.9 For this
analysis, the initial deﬁnition of sample size was not applicable; the analysis
was conducted as a post hoc long-term observational study of patients
enrolled in the HD2000 trial. All participants in this study were included in
this intention-to-treat analysis, and only those with major violations of
inclusion criteria were not considered evaluable.
PFS was deﬁned as the time from the date of diagnosis to the date of
last observation, progression, relapse, or death resulting from any cause.
OSwas computed from the date of diagnosis to the date of last follow-up or
death resulting from any cause. FFS was calculated from the date of
diagnosis to the date of last follow-up or one of the following events:
response other than complete remission (CR), relapse, or death resulting
from any cause.
Survival curves were calculated using the Kaplan-Meier estimates,
and statistical comparison between curves was performed using the log-
rank test.14 Effect size was reported as a hazard ratio (HR) with a 95% CI
and estimated using the Cox proportional hazards (PH) regression
method, adjusted by the international prognostic score of Hasenclever.15,16
The proportionality of the hazard risk was graphically checked using the
scaled Schoenfeld residuals method.17 The risk of secondary malignancies
was reported as a cumulative incidence function, with death as a competing
risk, using the Gooley method18; comparisons between curves were
performed using the Gray test. Toxicity was evaluated using standard
ECOG criteria.19
Continuous variables were reported as medians and categorical
variables as frequencies (absolute and percentage). Comparisons between
categorical variables were examined using the x2 or Fisher exact test, and
continuous variables were analyzed by means of the Kruskal-Wallis test. All
reported tests were two sided, and any P value , .05 was considered to
indicate moderate strength of evidence against the null hypothesis. P values
were not adjusted for multiple comparisons. The analysis was performed
according to the intention-to-treat approach, except for studies involving
second malignancies and late adverse events, which were analyzed
according to actual therapy received.
RESULTS
From April 2000 to June 2007, 307 patients were registered in this
study; 12 were subsequently excluded: four in the ABVD arm
(missing data, n = 3; lost to follow-up, n = 1), four in the
BEACOPP arm (revised histology, n = 1; not compliant, n = 1;
missing data, n = 2), and four in the CEC arm (missing data, n = 3;
lost to follow-up, n = 1). On the basis of intention to treat, 99, 98,
and 98 patients were randomly assigned to receive ABVD, BEACOPP,
or CEC, respectively (Fig 1).
The main characteristics of the 295 eligible and assessable
patients, along with treatment details and dose-intensity of therapy,
were described in the original report.9 RT was administered in
46%, 44%, and 43% of patients randomly assigned to ABVD,
BEACOPP, or CEC, respectively (P = .871). At the end of all
therapy, including RT, the CR rate was 84% with ABVD, 91% with
BEACOPP, and 83% with CEC.
The median follow-up for the entire group of patients was
120 months (range, 4 to 169 months). Overall, 80 PFS events were
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recorded (24 progressions, 43 relapses, and 13 deaths resulting
from any cause), including an additional 21 episodes compared
with the initial report (13 relapses and eight deaths [seven resulting
from second malignancies and one resulting from toxicity of
salvage treatment]). By therapy arm, ﬁve, 11, and ﬁve new events
occurred in the ABVD, BEACOPP, and CEC arms, respectively
(Table 1). Among patients experiencing relapse, no signiﬁcant
deviation from the planned dose-intensity of the assigned therapy
was observed (data not shown).
Ten-year PFS rates were 69% (95% CI, 58% to 77%), 75%
(95% CI, 64% to 83%), and 76% (95% CI, 66% to 84%) for
patients randomly assigned to ABVD, BEACOPP, or CEC,
respectively (Fig 2). The HR for PFS adjusted for International
Prognostic Score (0 to 2 v 3 to 7) for BEACOPP versus ABVD was
0.73 (95% CI, 0.42 to 1.24); it was 0.72 (95% CI, 0.42 to 1.24) for
CEC versus ABVD.
The HR of BEACOPP versus ABVD lacked the proportionality
of risk that was missed after approximately 30 months of follow-
up. BEACOPP was associated with a 52% risk reduction compared
with ABVD (HR, 0.48; 95% CI, 0.25 to 0.93) during the ﬁrst
30 months of observation, whereas in subsequent follow-up, a
non-negligible rate of events (six deaths) was observed only in the
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(N = 307)
CEC
(n = 102)
ABVD
(n = 103)
BEACOPP
(n = 102)
Excluded
(n = 0)
Excluded
Revised histology
Not compliant
(n = 2)
(n = 1)
(n = 1)
Excluded
(n = 0)
(n = 103)
(n = 3)
(n = 1)
Eligible
Missing data
Lost to follow-up
Eligible
Missing data
(n = 100)
(n = 2)
Eligible
Missing data
Lost to follow-up
(n = 102)
(n = 3)
(n = 1)
In analysis
Full course
Partial course
In analysis
Full course
Partial course
In analysis
Full course
Partial course
(n = 99)
(n = 90)
(n = 9)
(n = 98)
(n = 88)
(n = 10)
(n = 98)
(n = 86)
(n = 12)
Fig 1. CONSORT diagram. Treatment allo-
cation and number of patients included in the
analysis. ABVD, doxorubicin, bleomycin, vin-
blastine, anddacarbazine;BEACOPP,bleomycin,
etoposide, doxorubicin, cyclophosphamide,
vincristine, procarbazine, and prednisone;
CEC, cyclophosphamide, lomustine, vindesine,
melphalan, prednisone, epidoxorubicin, vincris-
tine, procarbazine, vinblastine, and bleomycin.
Table 1. Events and Causes of Death Recorded at Last Follow-Up by Treatment Arm
Event or Cause of Death
ABVD (n = 99) BEACOPP (n = 98) CEC (n = 98)
Early Update Total Early Update Total Early Update Total
Event (PFS)
Progression 12 — 12 2 — 2 10 — 10
Relapse 14 5 19 8 5 13 8 3 11
Death resulting from any cause — — 4 6 10 1 2 3
Total 26 5 31 14 11 25 19 5 24
Cause of death
Progression 7 4 11 4 1 5 5 3 8
Toxicity
First line — — — 2 — 2 — — —
Second line 1 1 2 2 1 3 1 1 2
Second malignancy — — — — 5 5 1 2 3
Unknown — — — — — — — 1 1
Total 8 5 13 8 7 15 7 7 14
NOTE. Early indicates data recorded by Federico et al9 in 2009; update indicates data recorded at last follow-up in 2014.
Abbreviations: ABVD, doxorubicin, bleomycin, vinblastine, and dacarbazine; BEACOPP, bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, pro-
carbazine, and prednisone; CEC, cyclophosphamide, lomustine, vindesine, melphalan, prednisone, epidoxorubicin, vincristine, procarbazine, vinblastine, and bleomycin;
PFS, progression-free survival.
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BEACOPP arm (HR, 1.70; 95% CI, 0.72 to 4.02) when compared
with ABVD (zero events; Table 2; Fig 3).
With regard to the analysis of FFS, 41 patients did not achieve
CR, 43 developed relapses, and seven died as a result of causes
unrelated to lymphoma. Ten-year FFS results were 65% (95% CI,
54% to 73%), 73% (95%CI, 62% to 81%), and 71% (95% CI, 61%
to 79%) for ABVD, BEACOPP, and CEC, respectively (Fig 2). For
FFS, the HR between BEACOPP and ABVD did not follow the
proportionality of risk with changing time after 30 months of
follow-up (data not shown).
In the group of 84 patients who did not achieve CR or
experienced progressive or relapsed HL, salvage data were available
for 73 (87%). Among them, three (4%) died before salvage therapy
could begin, 26 (36%) received conventional chemotherapy,
40 (55%) underwent SCT, and four (5%) were treated with RT
alone. Among the patients for whom induction therapy failed, 15
(two with refractory disease and 13 after relapse), 12 (one with
refractory disease and 11 after relapse), and 13 (three with
refractory disease and 10 after relapse) were treated with SCT in the
ABVD, BEACOPP, and CEC arms, respectively.
With updated follow-up, 42 deaths were recorded: 24 resulting
from lymphoma progression, two resulting from toxicity of initial
therapy, seven resulting from toxicity of salvage therapy, and eight
resulting from second malignancies; in one patient, the cause of
death was unknown. Compared with those reported in 2009, eight
additional deaths occurred as a result of lymphoma progression
and seven as a result of second malignancies (Table 1). The dis-
tribution of deaths attributable to HL by randomized arm was 11
with ABVD, ﬁve with BEACOPP, and eight with CEC (P = .022). At
10 years of follow-up, no signiﬁcant differences emerged among
the three arms in terms of OS results: 85% (95% CI, 75% to 91%)
with ABVD, 84% (95% CI, 74% to 90%) with BEACOPP, and 86%
(95% CI, 77% to 92%) with CEC (P = .892; Fig 2).
Analysis of second malignancies was based on the actual
treatment. Sixteen patients received chemotherapy that was dif-
ferent from that originally intended, because of physician or
patient choice: one patient randomly assigned to ABVD received
CEC, nine patients randomly assigned to BEACOPP received
ABVD, and six patients randomly assigned to CEC received ABVD.
Thirteen second malignancies occurred in this trial: one after
ABVD, six after BEACOPP, and six after CEC treatment (Table 3).
All second malignancies but one were diagnosed in patients in CR,
and eight resulted in death (seven of these eight patients were in
ﬁrst CR). Five of 13 had received RT as part of their initial
treatment. Three of these developed a solid tumor within or close
to an irradiated ﬁeld (lung cancer and pleural sarcoma after
treatment with BEACOPP and irradiation of the mediastinum;
thyroid carcinoma after ABVD and irradiation of the media-
stinum). The median time from the end of treatment for HL and
diagnosis of second malignancy was 90 months (range, 4 to
153 months). The second malignancy crude rate was 5.0 3 1,000
person-years (95% CI, 2.9 to 8.7), and the overall 10-year
cumulative incidence rate was 4.2% (95% CI, 2.1% to 8.8%). The
cumulative incidence rates at 10 years after ABVD, BEACOPP, and
CEC were 0.9% (95% CI, 0.1% to 4.5%), 6.6% (95% CI, 2.4% to
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Fig 2. (A) Overall, (B) progression-free, and (C) failure-free survival stratiﬁed by
treatment arm. ABVD, doxorubicin, bleomycin, vinblastine, and dacarbazine;
BEACOPP, bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine,
procarbazine, and prednisone; CEC, cyclophosphamide, lomustine, vindesine,
melphalan, prednisone, epidoxorubicin, vincristine, procarbazine, vinblastine, and
bleomycin.
Table 2. PFS and Relative Risk Between BEACOPP and CEC With ABVD as
Reference Using Cox Proportional Hazards Regression
Treatment
10-Year PFS
% (95% CI) HR (95% CI) P
ABVD 69 (58 to 77) 1.00
BEACOPP 75 (64 to 83)
Follow-up, months
# 30 0.48 (0.25 to 0.93) .031
. 30 1.70 (0.72 to 4.02) .228
CEC 76 (66 to 84) 0.73 (0.42 to 1.25) .249
IPS 3-7 65 (55 to 73) 1.65 (1.06 to 2.58) .028
Abbreviations: ABVD, doxorubicin, bleomycin, vinblastine, and dacarbazine;
BEACOPP, bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine,
procarbazine, and prednisone; CEC, cyclophosphamide, lomustine, vindesine,
melphalan, prednisone, epidoxorubicin, vincristine, procarbazine, vinblastine,
and bleomycin; HR, hazard ratio; IPS, International Prognostic Score; PFS,
progression-free survival.
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13.8%), and 6% (95%CI, 1.8% to 13.9%), respectively (P= .02; Fig
4). The differences were signiﬁcant for both BEACOPP versus
ABVD (P = .027) and CEC versus ABVD (P = .02). A list of
nononcologic late events is provided in Appendix Table A1 (online
only).
DISCUSSION
In this report, we provide a 10-year follow-up analysis of the
HD2000 trial, which compared six cycles of ABVD, four cycles of
e-BEACOPP followed by two of s-BEACOPP, and six cycles of CEC
as initial treatment for patients with advanced HL. Ten-year PFS
results were 69%, 75%, and 76% (P = .471) for ABVD, BEACOPP,
and CEC arms, respectively; corresponding 10-year OS results were
85%, 84%, and 86% (P = .892). In comparison with our prior
analysis, we have conﬁrmed better control of disease with BEACOPP
compared with that observed following ABVD; however, this beneﬁt
was counterbalanced by a statistically higher rate of late major events
after BEACOPP, particularly second malignancies, which resulted in
patients’death, a ﬁnding that was also observed for patients who had
received CEC.
The OS results in this trial with BEACOPP are similar to those
reported in an analysis of the GHSG HD9 study, in which 86% of
patients who received e-BEACOPP were still alive at 10 years.8 The
cumulative risk of second malignancies in that study was 6.5%,
similar to that observed in our trial. However, the risk of second
malignancies after ABVD in our study was low, resulting in OS
rates similar to those reported after BEACOPP. Both the sequential
COPP-ABVD arm in the HD9 trial and the CEC regimen in the
HD2000 trial were associated with rates of second malignancies
that were similar to those associated with BEACOPP, possibly
because of the high doses of alkylating agents in these regimens.
Forty-ﬁve percent of our patients received consolidative RT. This
may also have contributed to an increased risk of development of
second malignancies in our trial, although the number of patients
receiving RT was similar among the three study arms.
Recently, Skoetz et al20 from the GHSG reported results of a
meta-analysis comparing BEACOPP and ABVD; in that study,
there was a 10% OS beneﬁt favoring BEACOPP. However, these
results were reported after only 5 years of follow-up, and 10-year
results may be needed to clarify this improvement in risk of death
after the more intensive regimen.
The value of long-term analysis after treatment of patients has
been conﬁrmed by investigators of the NCIC Clinical Trials Group/
ECOG HD6 trial.21 Although patients in that study had limited-
stage HL and received therapy possibly considered outmoded in
the modern era, better early control of HL with more intensive
therapy did not translate into a survival advantage, because of late
events unrelated to the disease.
To put the results of our study into proper context, we
acknowledge the limitations of our study, which was not powered
to demonstrate differences in terms of OS. However, aside from
strict statistical considerations, we believe the differences in results
with these regimens after prolonged observation time are relevant
from a clinical point of view. So far, only the HD9 and HD2000
trials have provided 10-year survival data on advanced HL. Mature
follow-up results of other, larger randomized trials comparing
ABVD and BEACOPP should be strongly encouraged to conﬁrm
these observations.9-12
For the time being, we suggest that BEACOPP is an option for
treatment of advanced HL, but it should not be considered the
standard for all patients, because 70% of these patients may be
cured with ABVD and limited RT. Moreover, considering the
young age of patients with HL and the long-term toxicity of
BEACOPP found in our study, a careful assessment of the risk–
beneﬁt ratio of the initial treatment choice is warranted. Although
the International Prognostic Score for HL is commonly used to
assess the risk of disease progression in trials for HL, the value of
this prognostic index as a method of choosing therapy for
advanced HL has not yet been validated. Moreover, PET has been
suggested as a strong prognostic factor when used to assess early
response during ABVD treatment.22-24 Several randomized trials
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Fig 3. Smoothed hazard function of the three treatment arms. The bleomycin,
etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and pre-
dnisone (BEACOPP) arm showed a nonproportionality of the hazard compared
with the doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) arm. Thus, in
the Cox proportional hazards regression, the effect of BEACOPP was modeled
with a time-varying coefﬁcient; the hazard ratio was reported in early (, 30months)
and late follow-up (. 30 months). CEC, cyclophosphamide, lomustine, vindesine,
melphalan, prednisone, epidoxorubicin, vincristine, procarbazine, vinblastine, and
bleomycin.
Table 3. Secondary Malignancies by Treatment Arm
Second Malignancy
ABVD
(n = 113)
BEACOPP
(n = 89)
CEC
(n = 93)
Bladder carcinoma — — 3
Lung carcinoma — 2 —
Thyroid carcinoma 1 — —
Kaposi’s sarcoma — 1 —
Pleural sarcoma — 1 —
Breast cancer — — 1
Follicular lymphoma (grade 3a) — — 1
Non-Hodgkin lymphoma (T cell) — 1 —
Acute myeloid leukemia — 1 —
Myelodysplastic syndrome — — 1
Total 1 6 6
Abbreviations: ABVD, doxorubicin, bleomycin, vinblastine, and dacarbazine;
BEACOPP, bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine,
procarbazine, and prednisone; CEC, cyclophosphamide, lomustine, vindesine,
melphalan, prednisone, epidoxorubicin, vincristine, procarbazine, vinblastine,
and bleomycin.
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have been conducted investigating the role of early PET as a
decisional tool, and early data have conﬁrmed the value of this
approach to treatment management.25-27 In most of these studies,
ABVD was chosen as initial treatment, and early positive PET
ﬁndings were used to identify patients at high risk of progression,
who were then shifted to more-intense chemotherapy regimens,
including BEACOPPor high-dose chemotherapy and SCT. In these
studies, patients with negative early PET ﬁndings subsequently
received modiﬁed versions of ABVD, with the aim of further
reducing the risks of both acute and late toxicities. Such response-
adapted approachesmay be appropriate treatment strategies, although
they have yet to be included in standardmanagement of advancedHL.
Finally, promising agents have been developed that seem
highly active in therapy for relapsed HL. The immunoconjugate
anti-CD30 antibody brentuximab vedotin has been recently approved
for treatment of relapsed refractory HL and, combined with AVD, is
currently being compared with ABVD in a randomized trial for the
initial therapy of advanced disease.28,29 In another trial conducted by
the GHSG, brentuximab vedotin is being used to create a targeted
BEACOPP variant that could result in a regimen that is equally
effective but less toxic than e-BEACOPP (ClinicalTrials.gov identiﬁer,
NCT01569204). More recently, two drugs targeting programmed
death 1, namely nivolumab and pembrolizumab, also demonstrated
promising activity in patients with relapsed or refractory disease, and
their use in HL will be developed.30,31
In conclusion, mature follow-up results of the HD2000 trial
demonstrated excellent outcomes for patients with advanced HL,
which were achieved with either ABVD or BEACOPP, although
these combinations have different activity and toxicity proﬁles.
With the availability of PET for the early assessment of patient risk
and of new drugs characterized by high response rates and
favorable safety proﬁles, we believe it is time to move from the “old
ﬁght” between ABVD and BEACOPP to the development of an
integrated and more personalized approach for each patient.
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Appendix
Table A1. Late Nononcologic Adverse Events by Treatment Arm
Adverse Event
ABVD
(n = 113)
BEACOPP
(n = 89)
CEC
(n = 93)
Cardiopathy 3 1 2
Femoral head necrosis 1 2
Thyroid dysfunction 1 3
Autoimmune hemolytic anemia 1
Epilepsy 1
Pulmonary ﬁbrosis 1
Peripheral neuropathy 1
Parkinson’s disease 1
Parathyroid adenoma 1
Total 5 5 9
Abbreviations: ABVD, doxorubicin, bleomycin, vinblastine, and dacarbazine;
BEACOPP, bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine,
procarbazine, and prednisone; CEC, cyclophosphamide, lomustine, vindesine,
melphalan, prednisone, epidoxorubicin, vincristine, procarbazine, vinblastine,
and bleomycin.
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